You are here: Industry Insights > Market News > Shanghai Fosun Pharmaceutical Group, Shandong Buchang Pharmaceutical, 4SC

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Shanghai Fosun Pharmaceutical Group, Shandong Buchang Pharmaceutical, 4SC

pharmaceutical-technologyMay 27, 2017

Tag: china , Shares

Favorites

Shanghai Fosun Pharmaceutical Group intends to raise approximately HK$2.32bn ($298.3m) through a private placement of 80.6 million shares.

Priced at HK$28.8 ($3.7) a share, the placement includes a 90-day lock-in period from the closing date.

The proceeds will be used to repay the company’s interest-bearing debts, supplement the working capital, and to fund inorganic growth efforts.

Shanghai Fosun Pharmaceutical Group is a pharmaceutical company based in China.

Shandong Buchang Pharmaceutical has entered an agreement with Sihuan Pharmaceutical Holdings Group for the distribution of two Guhong and Troxerutin and cerebroprotein hydrolysate injections.

Both companies involved in the transaction are pharmaceutical firms based in China.

Previous:NPPA issues notice to pharmaceutical firms for non-compliance of pricing provisions

Next:Shareholder suit targets NewLink management over failed cancer vaccine trial

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Shanghai Fosun Pharmaceutical Group, Shandong Buchang Pharmaceutical, 4SC | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

China manufacture supplier competitive price Salidroside Natural Rhodiola Rosea Extract

China Supply Industry Grade White Flake Crystal 990 %min Industry Garde TMP Trimethylolpropane

Sulfadiazine USP/BPsupplier API Pharmaceutical Sulfonamides made in china

Osthole 35% Plant extract Pharmaceutical supplier API made in china

Vancomycin USP supplier Pharmaceutical API Antibiotic made in china

Berberine chloride hydrate CP2010/ JP13 API Pharmaceutical made in china

China factory direct supply Competitive Price Trimellitic Anhydride CAS 552-30-7 with free samples i

China factory direct supply Favorable Price Polyoxyethylene stearate with cas

China factory direct supply Zinc carbonate CAS 3486-35-9 with free sample in stock

Diclazuril CPV Pharmaceutical API Anticoccidial drugsAnti parasite Veterinary made in china

Shanghai Fosun Pharmaceutical Group, Shandong Buchang Pharmaceutical, 4SC

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>